Abstract: The present disclosure is directed to the use of perlecan compositions to reduce the risk of mortality in subjects due to neurological injury such as stroke, including large vessel occlusion, and traumatic brain injury. The disclosure is also directed to the use of perlecan compositions to reduce mortality in stroke patients treated with tPA.

Abstract: This invention relates in general to the field of cell-therapy treatments and more particularly, but not by way of limitation, to systems and methods for administering personalized cell-therapy treatments intravenously. In various embodiments, the system may calculate an aspiration volume needed for centrifugation to achieve a concentrated target threshold dose of 2.5×106 platelets/?L for a particular cell therapy using various factors such as, for example, information about a patient and the efficiency of the concentration process.

Abstract: The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.

Abstract: The present disclosure provides matrix compositions comprising bioactive glass and methods for treating a defect in tissue demonstrating volumetric tissue loss arising from injury or congenital defect.

Abstract: The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.

Abstract: The present invention provides a method for expanding a population of chondrocytes that maintains chondrocyte phenotype during the expansion by culturing the population in a defined serum-free expansion medium containing one or more cytokines and under low attachment conditions. The method further solves diffusion problems during the subsequent stage of extracellular matrix production by use of a perforated polycarbonate substrate that results in a randomly organized cultured neocartilage tissue. Chondrocytes expanded and cultured in this manner can be used in various medical applications to repair cartilaginous tissues that have been injured by trauma or disease.

Abstract: The present invention provides a method that maintains chondrocyte phenotype during serial expansion by culturing a population of chondrocytes in a defined serum-free culture medium containing cytokines and on a substrate that is modified by covalent attachment of hyaluronic acid. The underlying principle is to maintain native chondrocyte phenotype by growing the dissociated chondrocytes on a substrate modified by covalent attachment of hyaluronic acid to retain native chondrocyte morphology and function. Chondrocyte expanded in this manner can be used in various medical applications to repair cartilaginous tissues that have been injured by trauma or disease. This substratum provides a microenvironment that more closely mimics that of native articular cartilage, thereby promoting chondrogenesis in a predictable manner.